Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | OPRM1 | P35372 | 9/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.51 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12273135 | 0.94 | LMNA (0.68) | LMNAMEN1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL6737966 | 0.91 | OPRM1 (0.67) | LMNAMEN1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL16423615 | 0.91 | LMNA (0.58) | LMNAMEN1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL12649534 | 0.88 | OPRM1 (0.56) | LMNAMEN1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL23011158 | 0.86 | LMNA (0.53) | LMNAMEN1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1465773 | 0.83 | MEN1 (0.54) | LMNAMEN1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL16280746 | 0.82 | MEN1 (0.54) | LMNAMEN1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL10318609 | 0.80 | OPRM1 (0.60) | OPRM1OPRD1OPRK1SLC22A1SLC6A4 | |
| SCHEMBL1769439 | 0.79 | ALDH1A1 (0.47) | LMNAMEN1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL5072121 | 0.79 | LMNA (1.00) | LMNAMEN1CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11364220-B2 | Compounds and methods for inhibiting CPY26 enzymes | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2022-06-21 | — | — | US | disclosed |
| US-20210220326-A1 | Compounds and Methods for Inhibiting CPY26 Enzymes | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2021-07-22 | — | — | US | disclosed |
| US-10874634-B2 | Compounds and methods for inhibiting CYP26 enzymes | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2020-12-29 | — | — | US | disclosed |
| US-9187453-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-11-17 | — | — | US | disclosed |
| US-20150094296-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-04-02 | — | — | US | disclosed |
| EP-2832734-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-02-04 | — | — | EP | disclosed |
| CN-102648178-B | Quinazoline derivatives | MERCK PATENT GMBH | 2015-01-07 | — | — | CN | disclosed |
| US-8906930-B2 | Quinazoline derivatives | MERCK PATENT GMBH (DE) | 2014-12-09 | — | — | US | disclosed |
| US-8906930-B2 | Quinazoline derivatives | MERCK PATENT GMBH (DE) | 2014-12-09 | — | — | US | disclosed |
| US-20120238582-A1 | QUINAZOLINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-09-20 | — | — | US | disclosed |
| US-20120238582-A1 | QUINAZOLINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-09-20 | — | — | US | disclosed |
| CN-102648178-A | Quinazoline derivatives | MERCK PATENT GMBH | 2012-08-22 | — | — | CN | disclosed |
| WO-2011061760-A1 | NOVEL ANTITHROMBOTIC AGENTS | CADILA HEALTHCARE LIMITED (IN) | 2011-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150094296-A1 | HETEROCYCLIC COMPOUND | TYK2, SSB, UACA | LMNA 2866/4885MEN1 1167/4885CYP1A2 2832/4885 |
| US-10874634-B2 | Compounds and methods for inhibiting CYP26 enzymes | CYP26B1, CYP2A6, CYP26A1 | LMNA 2720/4885MEN1 4657/4885CYP1A2 32/4885 |
| US-11364220-B2 | Compounds and methods for inhibiting CPY26 enzymes | CYP2A6, CYP27A1, CYP26B1 | LMNA 3766/4885MEN1 4752/4885CYP1A2 84/4885 |
| US-20120238582-A1 | QUINAZOLINE DERIVATIVES | HSP90AB1, HSP90AA1, HSP90B1 | LMNA 3128/4885MEN1 4488/4885CYP1A2 446/4885 |
| US-20210220326-A1 | Compounds and Methods for Inhibiting CPY26 Enzymes | CYP2A6, CYP27A1, CYP26B1 | LMNA 3922/4885MEN1 4793/4885CYP1A2 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.